000			01629 a2200457 4500
005			20250517070457.0
264		0	_c20160425
008			201604s 0 0 eng d
022			_a1759-4782
024	7		_a10.1038/nrclinonc.2015.216 _2doi
040			_aNLM _beng _cNLM
100	1		_aGardner, Eric E
245	0	0	_aDrug therapy: Preclinical oncology - reporting transparency needed. _h[electronic resource]
260			_bNature reviews. Clinical oncology _cJan 2016
300			_a8-9 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xtherapeutic use
650	0	4	_aCarcinoma, Neuroendocrine _xdrug therapy
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aClinical Trials as Topic
650	0	4	_aEvidence-Based Medicine
650	0	4	_aGastrointestinal Stromal Tumors _xdrug therapy
650	0	4	_aHumans
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aKidney Neoplasms _xdrug therapy
650	0	4	_aMedical Oncology
650	0	4	_aMeta-Analysis as Topic
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aPancreatic Neoplasms _xdrug therapy
650	0	4	_aPractice Guidelines as Topic
650	0	4	_aPyrroles _xtherapeutic use
650	0	4	_aResearch Design
650	0	4	_aResearch Report _xstandards
650	0	4	_aStomach Neoplasms _xdrug therapy
650	0	4	_aSunitinib
650	0	4	_aTreatment Outcome
700	1		_aRudin, Charles M
773	0		_tNature reviews. Clinical oncology _gvol. 13 _gno. 1 _gp. 8-9
856	4	0	_uhttps://doi.org/10.1038/nrclinonc.2015.216 _zAvailable from publisher's website
999			_c25542088 _d25542088